Evolus, Inc. recently held its Q4 2025 Earnings Call, where they highlighted several key achievements and future plans. Despite a challenging year with declining U.S. injectable volumes, Evolus managed to achieve a 12% full-year revenue growth. This success was attributed to their strategic approach, particularly with Jeuveau capturing a 14% market share by focusing on cash-pay aesthetic practices.
One notable initiative was the introduction of a new portfolio growth rebate program aimed at incentivizing accounts to consolidate their toxin and filler spend with Evolus. This program, along with the expansion of the Evolysse HA filler footprint to over 3,000 purchasing accounts, showcased the company’s commitment to meeting consumer demand for natural-looking results.
In terms of international expansion, Evolus saw significant growth, with revenues nearly doubling year-over-year. This growth was driven by a transition to a direct model in Germany and approaching double-digit market share in the U.K. Additionally, the company maintained brand resilience through Evolus Rewards, a loyalty program that has grown to over 1.4 million treated patients.
Looking ahead, Evolus is projecting total net revenue between $327 million and $337 million for 2026. They anticipate achieving full-year profitability with low to mid-single-digit adjusted EBITDA margins. The company is also planning the European launch of Estyme in the second quarter of 2026 and expects FDA approval of Evolysse Sculpt in the fourth quarter.
To support their growth and upcoming product launches, Evolus implemented a new revolving credit facility providing up to $40 million in liquidity. They also emphasized their commitment to maintaining shareholder value by avoiding raising equity capital.
Overall, Evolus is optimistic about the future, with targets of $450 million to $500 million in revenue by 2028. With a focus on innovation, strategic partnerships, and customer loyalty, the company is poised for continued success in the competitive aesthetics market.
